LIVE

TLX

Telix Pharmaceuticals Limited

TLX

NASDAQ·Healthcare·Biotechnology·Mkt cap $4.0B

$11.87

+0.25%

View full research view

Our plain-language verdict, the thesis, risk factors, and what is changing about the business.

View research view

52-Week Range

$6.28 - $16.98

P/E

Fwd P/E

79.53

Beta

0.59

Div Yield

0.00%

Avg Vol

188.1K

Shares Out

Mkt Cap

$4.0B

Price action

Price chart

Down 28.2% over the trailing year

1W
1M
3M
6M
YTD
1Y
5Y
MAX

Total returns

Price performance

Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.

Why we rate it this way

The thesis at a glance

Bull and bear case · plain-English context across the five lenses we evaluate.

Bull Case

No bull reasons captured for this rating yet.

Bear Case

2 risks

  • Low volatility (beta 0.6).
  • Extreme premium - high expectations embedded

Growth

Revenue decline expected

Value

Extreme premium - high expectations embedded

Momentum

Hot

+29.7% over 3m

Quality

Strong

Mixed fundamentals

Dividend

None

No dividend

Earnings track record

Recent earnings results

AI-summarized recap of last quarter, plus the surprise on every print.

Next: Aug 20, 2026

LATEST RECAP

Earnings recap unavailable for this period.

EPS surprise · last 4Q

No quarterly earnings data on file.

Next: Aug 20, 2026

Wall Street consensus

2 analysts · 100% Buy

Live ratings and price targets aggregated across covering analysts.

Buy

2

100%

Hold

0%

Sell

0%

Median Price Target

Latest: Wedbush · Apr 13, 2026

vs Industry

How TLX stacks vs Biotechnology

Stock metrics vs industry averages. Green = better than industry.

Industry comparison data unavailable for this stock.

Related

Peers & themes

Peers

No peer data available.

Themes

No themes assigned.